Cas9 Stable Cell Line - SiHa

The SiHa-Cas9 stable cell line is the preferred model for cervical cancer research. It is established by integrating the Cas9 nuclease into the human SiHa cell line. SiHa is an adherent epithelial cell line isolated from a 55-year-old woman with cervical squamous cell carcinoma. A significant characteristic of SiHa cells is the integration of a low copy number (approximately 1-2 copies per cell) of the human papillomavirus type 16 (HPV-16) genome. Constitutive expression of Cas9 in this cell line provides an efficient and reproducible platform for CRISPR-mediated gene editing, ensuring that the editing mechanism is always at its optimal level. This stable system eliminates the variability of transient transfection and provides a powerful tool for studying the molecular genetics and viral oncogenic mechanisms of HPV-related malignancies.

The primary application of the SiHa-Cas9 stable cell line is in studying the pathogenesis of cervical cancer and developing new therapeutic strategies. Researchers have used this cell line for large-scale CRISPR screening to identify genes involved in HPV E6/E7-mediated signaling pathways, cell cycle dysregulation, and resistance to radiotherapy and chemotherapy. The SiHa-Cas9 cell line is particularly suitable for constructing homologous clones with specific gene knockouts, enabling scientists to study the roles of tumor suppressor genes and oncogenes in cervical cancer progression. Furthermore, it serves as a reliable platform for evaluating the efficacy of targeted therapies and exploring molecular barriers to viral clearance. Its well-defined HPV-16 background and stable Cas9 expression make it an indispensable resource for advancing precision oncology in gynecological cancers and developing HPV-targeted interventions.